TABLE 2.

SARS spike protein peptides useda

Mixture 1Mixture 2Mixture 3Mixture 4
ResiduesSequenceResiduesSequenceResiduesSequenceResiduesSequence
257-272LKPTTFMLKYDENGTI343-360KKISNCVADYSVLYNSTF427-444NIDATSTGNYNYKYRYLR505-521NAPATVCGPKLSTDLIK
263-280MLKYDENGTTTDAVDCSQ351-367DYSVLYNSTFFSTFKCY435-451NYNYKYRYLRHGKLRPF 512-529 GPKLSTDLIKNQCVNFNF
271-287TITDAVDCSQNPLAELK358-374STFFSTFKCYGVSATKL442-458YLRHGKLRPFERDISNV 520-537 IKNQCVNFNFNGLTGTGV
278-295CSQNPLAELKCSVKSFEI365-382KCYGVSATKLNDLCFSNV449-465RPFERDISNVPFSPDGK528-545NFNGLTGTGVLTPSSKRF
286-300LKCSVKSFEIDKGIY373-390KLNDLCFSNVYADSFVVK456-472SNVPFSPDGKPCTPPAL536-553GVLTPSSKRFQPFQQFGR
291-308 KSFEIDKGIYQTSNFRVV 381-398NVYADSFVVKGDDVRQI463-478DGKPCTPPALNCYWPL544-558RFQPFQQFGRDVSDF
299-316IYQTSNFRVVPSGDVVRF389-406VKGDDVRQIAPGQTGVIA469-484PPALNCYWPLNDYGFY549-566QQFGRDVSDFTDSVRDPK
307-322VVPSGDVVRFPNITNL397-412IAPGQTGVIADYNYKL476-491WPLNDYGFYTTTGIGY557-573DFTDSVRDPKTSEILDI
313-329VVRFPNITNLCPFGEVF403-420GVIADYNYKLPDDFMGCV482-499GFYTTTGIGYQPYRVVVL 564-581 DPKTSEILDISPCSFGGV
320-337TNLCPFGEVFNATKFPSV411-428KLPDDFMGCVLAWNTRNI490-506GYQPYRVVVLSFELLNA572-590DISPCSFGGVSVITPGTNA
328-345VFNATKFPSVYAWERKKI419-436CVLAWNTRNIDATSTGNY497-514VVLSFELLNAPATVCGPK581-598VSVITPGTNASSEVAVLY
336-352SVYAWERKKISNGVADY
  • a Boldface type indicates peptides which completely inhibited neutralizing activity.